RSP Systems secures series B funding

RSP Systems Secures Series B Funding to Drive its Non-Invasive Glucose Monitor

Odense, Denmark, June 11, 2018 / B3C newswire / — RSP Systems A/S, the non-invasive diagnostics company, announces that it has completed the first closing of a Series B funding round amounting to US$7.7 million. The round remains open for a second closing due to strong interest. 

The proceeds of this round will be used to fund more extensive clinical trials, allowing RSP Systems to prepare for regulatory approval and market launch with a stand out product that will revolutionise diabetes management.

The Series B round included family offices and private investors, such as Jürgen Hambrecht, Chairman of the Board of BASF and Andreas Jenne, RSP Systems’ new CEO. All of RSP Systems’ present investors also participated in this round. Currently, RSP Systems has raised a total of US$23.1 million, including the Horizon 2020 grant awarded by the EU in 2016.

RSP Systems CEO, Andreas Jenne, commented: “The Series B financing round builds on an exceptional year for RSP Systems where the company has significantly advanced its technology platform, as featured in an article recently published in PLOS ONE.”

Share

Share on facebook
Share on twitter
Share on linkedin

More news

Digital health is a powerful force that can transform lives. To positively impact people’s health, digital health solutions have to be important …

Remember to Celebrate – and enjoy the journey This week we were visited by an assessor who executed our first ISO1345:2016 surveillance audit. The …

Digital health is a powerful force that will transform lives. RSP Systems’ non-invasive technology enables consumers to measure critical elements of blood …